Published in Eur J Clin Microbiol Infect Dis on December 01, 1994
The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother (1997) 2.84
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.02
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology (1993) 2.65
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)]. Pathol Biol (Paris) (1982) 2.18
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS (2000) 2.14
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Respiratory stroke volume variation assessed by oesophageal Doppler monitoring predicts fluid responsiveness during laparoscopy. Br J Anaesth (2013) 2.07
Predictability of the respiratory variation of stroke volume varies according to the definition of fluid responsiveness. Br J Anaesth (2014) 2.00
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med (1996) 1.82
Brucellosis from sniffing bacteriological cultures. Lancet (1997) 1.70
Mandatory prenatal screening for the human immunodeficiency virus: the experience in south-eastern France of a national policy, 1992-1994. Br J Obstet Gynaecol (1998) 1.68
Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother (1989) 1.62
The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr (2001) 1.51
Gradient plate method to induce Streptococcus pyogenes resistance. J Antimicrob Chemother (1999) 1.50
Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful? Clin Microbiol Infect (2010) 1.46
Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol (1995) 1.44
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med (2011) 1.43
Klebsiella pneumoniae strains more resistant to ceftazidime than to other third-generation cephalosporins. J Antimicrob Chemother (1987) 1.42
[Prognosis of acute tuberculous respiratory distress syndrome. 4 cases]. Presse Med (1995) 1.39
Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat (2007) 1.39
[Aspergillus fumigatus muscle abscess revealing invasive aspergillosis in a patient with AIDS]. Presse Med (1998) 1.38
Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother (1990) 1.35
[Distribution of constituent beta-lactamases in Pseudomonas aeruginosa]. Presse Med (1984) 1.30
A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med (2009) 1.29
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med (2013) 1.28
HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis (2000) 1.28
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med (2001) 1.27
The population requirement for cataract extraction: a cross-sectional study. Eye (Lond) (2001) 1.25
Biotechnology and the European public. Nat Biotechnol (2000) 1.25
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther (2000) 1.24
Retracted Worlds apart? The reception of genetically modified foods in Europe and the U.S. Science (1999) 1.24
Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS (2000) 1.23
Comparative in vitro activity of 8 cephalosporins on 109 strains of Neisseria gonorrhoeae and 60 strains of Neisseria meningitidis. Chemotherapy (1981) 1.21
Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer (1999) 1.20
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia. J Exp Med (1992) 1.17
A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis (1999) 1.12
In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. J Antimicrob Chemother (2005) 1.10
Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol (2000) 1.10
Epidemiology of bacterial infection during management of open leg fractures. Eur J Clin Microbiol Infect Dis (1999) 1.08
Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of pseudomonas aeruginosa: a French multicentre study (1996). J Antimicrob Chemother (2000) 1.07
In the era of highly active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection? HIV Med (2005) 1.07
Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Community Health (2002) 1.07
A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia. Acta Derm Venereol (1991) 1.06
Effects of subinhibitory concentrations of vancomycin and teicoplanin on adherence of staphylococci to tissue culture plates. Antimicrob Agents Chemother (1993) 1.05
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med (2009) 1.05
Overexpression of Fas/CD95 and Fas-induced apoptosis in a patient with idiopathic CD4+ T lymphocytopenia. Clin Infect Dis (1999) 1.04
Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Arch Dermatol (1998) 1.04
Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis (2002) 1.03
Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol (1997) 1.03
Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis (1990) 1.03
Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer (2003) 1.01
Efficacy of subinhibitory concentration of pefloxacin in preventing experimental Staphylococcus aureus foreign body infection in mice. Drugs Exp Clin Res (1992) 1.00
Allopurinol for treatment of visceral leishmaniasis in patients with AIDS. J Infect Dis (1989) 0.98
Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc (2006) 0.98
Pneumococcal resistance patterns in Europe. Eur J Clin Microbiol Infect Dis (1997) 0.98
A decade-long surveillance of nasopharyngeal colonisation with Streptococcus pneumoniae among children attending day-care centres in south-eastern France: 1999-2008. Eur J Clin Microbiol Infect Dis (2011) 0.97
Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care (2010) 0.97
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis (2008) 0.97
Antibiotic misuse: a prospective clinical audit in a French university hospital. Eur J Clin Microbiol Infect Dis (2007) 0.97
Phase separation induced by melittin in negatively-charged phospholipid bilayers as detected by fluorescence polarization and differential scanning calorimetry. Biochim Biophys Acta (1982) 0.97
[The first isolation in France of a strain of Neisseria gonorrhoeae producing penicillinase]. Nouv Presse Med (1979) 0.96
Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction. J Protozool (1992) 0.96
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med (1997) 0.96
Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol (1994) 0.96
HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg (2002) 0.95
Hepatobiliary scintigraphy in infancy. J Nucl Med (1998) 0.95
A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France. J Antimicrob Chemother (1992) 0.95
Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med (2006) 0.94
Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother (1994) 0.94
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients. Clin Exp Immunol (1999) 0.93